Harmony Biosciences Holdings, Inc. HRMY 深 沪
已收盘 02-06 16:00:00 美东时间
37.27
+0.860
+2.36%
华盛通- 最 高37.54
- 今 开36.74
- 成交量 56.75万股
- 最 低 36.165
- 昨 收 36.41
- 总市值 21.47亿
- 52周最高 40.87
- 市盈率 静 14.82
- 换手率 0.99%
- 52周最低 25.52
- 委 比 -52.15%
- 总股本 5759.64万
- 历史最高 62.085
- 量 比 1.15
- 振 幅 3.78%
- 历史最低 18.6112
- 每 手 1
- 风险率 3.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created
01-29 09:20
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created
01-21 09:39
Harmony Biosciences Hldgs Raises FY2025 Sales Guidance from $845.000M-$865.000M to $868.000M vs $862.659M Est
Harmony Biosciences Hldgs (NASDAQ:HRMY) raises FY2025 sales outlook from $845.000 million-$865.000 million to $868.000 million vs $862.659 million estimate.
01-12 21:19
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Truist Securities Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $45
Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $48 to $45.
01-09 01:02
Beacon Biosignals Collaborates With Harmony Biosciences To Incorporate Quantitative EEG Measurements Into Two Of Harmony's Phase 3 Studies Of HBS-301 For Narcolepsy And Idiopathic Hypersomnia
Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and
2025-12-16 19:31
Harmony Biosciences To Highlight New Open-Label Extension Data From Its Investigation Of EPX-100 In Ongoing Phase 3 ARGUS Trial For Treatment Of Dravet Syndrome At 2025 AES Annual Meeting
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that it will highlight new open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS
2025-12-02 21:27
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $42 Price Target
Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $42 price target.
2025-11-24 23:03
